Psoriatic Arthritis News and Research

RSS

Like rheumatoid arthritis (RA), psoriatic arthritis is a chronic inflammatory disease of the joints and connective tissue. The disease causes joint pain and swelling that can lead to crippling along with inflamed and irritated scaly red patches of skin throughout the body. It is a progressive and debilitating disease and because there are no treatments specifically approved for psoriatic arthritis, doctors often use therapies approved for RA, including nonsteroidal anti-inflammatory drugs (NSAIDs) and disease modifying anti-rheumatic drugs (DMARDs). However, no DMARDs are currently approved for use in psoriatic arthritis. There are approximately 300,000 patients with psoriatic arthritis in the United States and the disease affects both men and women most commonly between the ages 30 and 50. Psoriatic arthritis patients are generally treated by rheumatologists and dermatologists.

New EULAR points-to-consider can help identify people at risk of psoriatic arthritis

The transition from psoriasis to PsA - and the early diagnosis of PsA - is of considerable scientific and clinical interest. People typically have psoriatic skin disease for a decade or more before they begin to experience the joint involvement of PsA.

17 Jul 2023

High BMI linked to increased risk of 5 rheumatic diseases

A new study by Uppsala University shows that a higher body mass index (BMI) increases the risk of five different rheumatic diseases: rheumatism, osteoarthritis, gout, psoriatic arthritis and inflammatory spondylitis. The researchers also noted that BMI was a stronger risk factor for women compared to men in terms of gout and psoriatic arthritis. The study will be presented in the journal Arthritis & Rheumatology.

26 Jun 2023

Study offers the most comprehensive archive of cellular, molecular features involved in psoriatic disease

Beneath and beyond the reddish, flaky lesions that form in the skin of those with psoriasis, mild and severe forms of the disease can be told apart by the activity of key cells and signaling pathways, a new study shows.

2 Jun 2023

Rheumatic and musculoskeletal diseases increase the risk of lethal comorbidities

Rheumatic and musculoskeletal diseases (RMDs) include over 200 diseases that affect over 120 million Europeans of all ages.

1 Jun 2023

Systematic approach needed to identify mental health issues in patients with inflammatory arthritis

Anxiety and depression are the mental health issues most commonly associated with inflammatory arthritis, and it is well-established that there is a link between mental health issues and poor health outcomes.

1 Jun 2023

Increased risk of cardiovascular disease in psoriatic arthritis patients

Patients with psoriatic arthritis (PsA) have an increased risk of cardiovascular disease, possibly due to a chronic inflammatory state.

1 Jun 2023

Long-term opioid use more common among patients with rheumatic and musculoskeletal conditions

Patients with rheumatic and musculoskeletal conditions are vulnerable to long term opioid use, with up to 1 in 3 of those with rheumatoid arthritis or fibromyalgia, who take these drugs for the first time, potentially at risk, suggest the findings of a research letter, published online in the Annals of the Rheumatic Diseases.

18 May 2023

Clinical trial shows efficacy and safety of brepocitinib for treating adults with psoriatic arthritis

Brepocitinib is an oral drug that inhibits certain enzymes involved in inflammation-;called tyrosine kinase 2 and Janus kinase 1-;and is being tested for the treatment of several immunological diseases.

17 May 2023

Investigating the impact of COVID-19 vaccinations in immunocompromised adult patients

In a recent study posted to the medRxiv* preprint server, researchers assessed the impact of third and fourth coronavirus disease 2019 (COVID-19) vaccination doses on immunity against COVID-19 among immunocompromised adult patients.

9 Mar 2023

Skin medication shows promise in treating alcohol use disorder

Researchers from Oregon Health & Science University and institutions across the country have identified a pill used to treat a common skin disease as an "incredibly promising" treatment for alcohol use disorder.

21 Feb 2023

Cardiovascular risk in psoriasis, the association between psoriatic inflammation and atherosclerosis, and the cardiovascular-risk-reducing effects of biologics

Researchers explored the impact of biological interventions in reducing cardiovascular risk among psoriasis patients.

6 Feb 2023

Glycan signatures in rheumatic diseases and their associated functional implications

A new paper examines the understanding of glycosylation in an array of rheumatic diseases and indicates the potential for therapeutic interventions using the same mechanism.

28 Nov 2022

Study estimates the quality of care for patients with long-term health conditions

The number of new diagnoses of rheumatoid arthritis fell by 20% in the first year of the COVID-19 pandemic, new research suggests.

4 Nov 2022

Dietary components do not have impact on RMD outcomes

In 2022, EULAR - the European Alliance of Rheumatology Associations - published new recommendations regarding lifestyle behaviors and work participation to prevent progression of rheumatic and musculoskeletal diseases (RMDs).

1 Nov 2022

Study finds an increase in the proportion of adults in England diagnosed with inflammatory arthritis

The proportion of adults in England diagnosed with inflammatory arthritis has increased by at least 40% between 2004 to 2020, new Keele University research has found.

25 Oct 2022

Total body PET/CT scans can effectively visualize systemic joint involvement in patients with arthritis

Total body PET/CT scans can successfully visualize systemic joint involvement in patients with autoimmune arthritis, according to new first-in-human research published in the October issue of The Journal of Nuclear Medicine.

14 Oct 2022

RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

With this approval, RINVOQ® is the first and only Janus Kinase inhibitor approved to treat patients across the spectrum of axial spondyloarthritis (nr-axSpA and ankylosing spondylitis) in the EU.

From AbbVie 29 Jul 2022

Scientists discover a key starting point for inhibiting inflammation in psoriasis and psoriatic arthritis

Around 250,000 people in Austria suffer from psoriasis. One third of them develop inflammation in their joints (psoriatic arthritis) as a result of the chronic skin condition.

6 Jul 2022

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

AbbVie today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of upadacitinib (RINVOQ® 15 mg, once daily) for the treatment of active non-radiographic axial spondyloarthritis (nr‑axSpA) in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).*

27 Jun 2022

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

27 Jun 2022

Psoriatic Arthritis News and Research

Further Reading

New EULAR points-to-consider can help identify people at risk of psoriatic arthritis

High BMI linked to increased risk of 5 rheumatic diseases

Study offers the most comprehensive archive of cellular, molecular features involved in psoriatic disease

Rheumatic and musculoskeletal diseases increase the risk of lethal comorbidities

Systematic approach needed to identify mental health issues in patients with inflammatory arthritis

Increased risk of cardiovascular disease in psoriatic arthritis patients

Long-term opioid use more common among patients with rheumatic and musculoskeletal conditions

Clinical trial shows efficacy and safety of brepocitinib for treating adults with psoriatic arthritis

Investigating the impact of COVID-19 vaccinations in immunocompromised adult patients

Skin medication shows promise in treating alcohol use disorder

Cardiovascular risk in psoriasis, the association between psoriatic inflammation and atherosclerosis, and the cardiovascular-risk-reducing effects of biologics

Glycan signatures in rheumatic diseases and their associated functional implications

Study estimates the quality of care for patients with long-term health conditions

Dietary components do not have impact on RMD outcomes

Study finds an increase in the proportion of adults in England diagnosed with inflammatory arthritis

Total body PET/CT scans can effectively visualize systemic joint involvement in patients with arthritis

RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

Scientists discover a key starting point for inhibiting inflammation in psoriasis and psoriatic arthritis

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News